Plasma Rich Growth Factors in Venous Ulcers
Recruitment status was: Not yet recruiting
OBJECTIVES: Main objective: To evaluate the effectiveness of plasma rich in growth factors (PRGF) in the treatment of patients with venous ulcers. Secondary objective: To evaluate the safety of plasma rich in growth factors in treating patients with venous ulcers. DESIGN: Randomized, open clinical trial in parallel groups, controlled with conventional treatment.
SAMPLE: Over age patients, of primary care centers of Vitoria, with at least one venous ulcers of 6 or more weeks of evolution and 0.5-6 cm of diameter. INTERVENTION: 1-Experimental group: Autologous PRGF administrated once a week (day 1) + conventional treatment administrated twice a week (days 1 and 4)for 12 weeks of treatment, but in those cases where there has been no complete healing in this period, patients will continue the same management protocol to get it. 2-Control group: Conventional treatment twice a week (days 1 and 4)for 12 weeks of treatment.
Conventional treatment includes: Cleaning and debridement of the wound, the application of corresponding dressing, and using of antibiotic if necessary in each visit.
STATISTICAL ANALYSIS:The primary outcome analysis was done by logistic regression. The crude model and the adjusted model (for confounding variables)will be built. The healing time of ulcers (in days) were analyzed using the Kaplan Meier survival analysis and the corresponding comparison using the log rank test.
|Venous Ulcers||Procedure: PRGF+ Cleaning, debridement of the wound, application of the corresponding dressing and using of antibiotics if necessary Procedure: Cleaning, debridement of the wound, application of the corresponding dressing and using of antibiotics if necessary|
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Randomized Clinical Trial to Determinate the Effectiveness and Safety of Plasma Rich Growth Factors (PRGF) in Venous Ulcers Treatment|
- Ulcers closed [ Time Frame: at 12 weeks of treatment ]Patients will be followed during 12 weeks.
- Pruritus (Yes/No) [ Time Frame: During 12 weeks of treatment (in each visit) ]
- Pain (through VAS scale) [ Time Frame: During 12 weeks of treatment (in each visit) ]
- Signs of infection (Yes/No) [ Time Frame: During 12 weeks of treatment (in each visit) ]
- Wound surface (in cm2) measured through PUSH scale [ Time Frame: Every 4 days ]
|Study Start Date:||November 2013|
|Estimated Study Completion Date:||November 2013|
|Estimated Primary Completion Date:||November 2013 (Final data collection date for primary outcome measure)|
Experimental: PRGF and conventional treatment
PRGF once a week (day 1) and conventional treatment twice a week (days 1 and 4)
Procedure: PRGF+ Cleaning, debridement of the wound, application of the corresponding dressing and using of antibiotics if necessary
PRGF once a week (day 1) and conventional treatment twice a week (days 1 and 4)during 12 weeks.
Types of dressing: enzyme cutting dressing (collagenase), hydrogel, polymeric foam, alginate dressing, hydrocolloid hydrofiber dressing, silver dressing, coal and silver dressing, argentum sulfadiazine dressing, polyurethane or caster hydrocolloid dressing
Active Comparator: Conventional treatment alone
Conventional treatment (cleaning, debridement of the wound and application of the corresponding dressing and using of antibiotics if necessary) twice a week (days 1 and 4).
Procedure: Cleaning, debridement of the wound, application of the corresponding dressing and using of antibiotics if necessary
Twice a week (days 1 and 4) during 12 weeks
An open, randomized, of parallel groups, and controlled clinical trial. Patients will be allocated on first come to one of the two treatment groups using a block random sequence generated by computer that will remain hidden from the researchers and patients until allocation.
Experimental group: PRGF together with the corresponding dressing according to annex IV.
Control group: Corresponding dressing according to annex IV.
Both groups will be submitted to a cleaning, debridement, occlusive dressing and use of antibiotic if necessary in each visit.
After signing consent form, and previously of randomization, patients will be submitted to a blood extraction where it will be determinate: Albumine (in g/dl), Hemoglobin (in g/dl), Hematocrit (in %), Creatinine (in mg/dl). If patients have data collected through previous analysis performed until 30 days before, it will not be necessary a new extraction.
Patients will be also submitted to an initial valuation of:
- medical antecedents: history of chronic venous insufficiency, previous medical treatments.
- general state: dependence grade through Barthel index, mobility, ankle arm index.
- ulcer characteristics:exudate, sing of location of ulcer, antiquity of ulcer, tunneling,infection, pain through a Visual Analogue Scale (VAS).
- Anthropometric characteristics; Weight, height and Body Mass Index (BMI).
Patients will go to the physician's consult every fours days (on Monday or Tuesday and Thursday or Friday). When one ulcer is closed, patient will go to physician's consult to confirm that it remains closed at seven and fifteen days.
In both intervention and control groups, the bad evolution of ulcer with deterioration at least during four consecutive weeks, will obligate to ask a preferred inter-consultation with Vascular Surgery Service.
In each visit the following variables will be measured:
- Wound surface (in cm2) measured through PUSH scale (Pressure Ulcer Scale for Healing) belonging to GNEAUPP group (National Group to study and advice about pressure ulcers and chronic wounds). This variable will be measured in each visit.
- Safety variable: Pruritus (Yes/No), Pain (through VAS scale), Sings of infection (Yes/No).
If patient experience one adverse effect which according to judgment of nurse precludes its continuation into the study, the nurse will communicate it to physician who will discharge from study if it is necessary.
All this will be collected in Case Report Form (CRF).
Please refer to this study by its ClinicalTrials.gov identifier: NCT01491438
|Contact: Javier Urraca||945006669||JAVIER.URRACAGARCIAMADINABEITIA@osakidetza.net|
|Javier Urraca García de Madinabeitia|
|Vitoria-Gasteiz, Álava, Spain|
|Principal Investigator:||Javier Urraca||Basque Public Health Service-Osakidetza|